Competence Center for Next-generation NK Cell-based Cancer Immunotherapy (NextGenNK)
| Reference number | |
| Coordinator | Karolinska Institutet - Institutionen för medicin, Huddinge |
| Funding from Vinnova | SEK 36 000 000 |
| Project duration | January 2020 - December 2024 |
| Status | Completed |
| Venture | Competence centre |
| Call | Kompetenscentrum 2020 |
Important results from the project
Yes, the initial goals have been achieved. NextGenNK has generated new patents, scientific publications, and clinical trials, strengthened Swedish SMEs, and established international collaborations. Key additional results include breakthroughs in genetically modified NK cells, optimized production processes, and increased research-based entrepreneurship. The project has positioned Sweden as a leader in NK cell therapy.
Expected long term effects
The project is expected to have long-term effects by establishing Sweden as a leader in NK cell therapy, attracting investments, and fostering new SMEs. Breakthroughs in genetically modified NK cells and optimized production methods may lead to more effective and accessible cancer treatments. The research has potential to strengthen industry competitiveness, creates jobs, and improves patient quality of life through innovative immunotherapies.
Approach and implementation
The project was carried out through close collaboration between academia, industry, and healthcare. NextGenNK, organized as a competence center, has integrated research, innovation, and clinical application. The focus has been on developing NK cell-based therapies, genetic modification, and clinical trials. The project has included international collaborations, training programs, and support for SMEs to drive commercialization and technological development.